ArticleKidney international2023
Discovery of seven novel putative antigens in membranous nephropathy and membranous lupus nephritis identified by mass spectrometry.
Article in Kidney international, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 52 citations in OpenAlex.
- MHC class II and PLA2R investigating the epitope presentation deficits driving antibody production in membranous nephropathy.International urology and nephrology · 2026Review
- Decoding Lupus Diagnosis, Pathogenesis and Therapy: From Systemic Autoimmunity to Renal Damage.Diagnostics (Basel, Switzerland) · 2026Review
- Optimization of a Target Antigen Diagnostic Pathway for Membranous Nephropathy.Kidney international reports · 2026Article
- Multiplexed Detection of Membranous Nephropathy Antigens by Multi-Reaction Monitoring Mass Spectrometry.Kidney international reports · 2026Article
- Beyond Titers: Phospholipase A2 Receptor Epitope Complexity as a New Lens in Membranous Nephropathy.Journal of the American Society of Nephrology : JASN · 2026Article
- Functional characterization of podocyte-expressed THSD7A in experimental membranous nephropathy.JCI insight · 2026Article
- A membranous nephropathy variant mimicking minimal change disease.The journal of pathology. Clinical research · 2026Article
- Antigens in membranous nephropathy: discovery and clinical implications.Nature reviews. Nephrology · 2025Review
- Repeat biopsies in membranous lupus nephritis in the era of target antigen identification.Virchows Archiv : an international journal of pathology · 2025Article
- The importance of identifying new and putative target antigens associated with membranous nephropathy: evidence from a Sardinian cohort.Clinical kidney journal · 2025Article
- Questions and Caveats in Antigen-Defined Membranous Nephropathy.Journal of the American Society of Nephrology : JASN · 2025Review
- Proteomics uncovers ICAM2 (CD102) as a novel serum biomarker of proliferative lupus nephritis.Lupus science & medicine · 2025Article
- Exploring glomeruli and renal tubules transcriptomic data: Crucial role of the AASS gene in membranous nephropathy.Clinical and translational medicine · 2025Article
- The spectrum and prognosis of Sjögren's syndrome with membranous nephropathy.Clinical kidney journal · 2025Article
- Membranous Nephropathy.Journal of clinical medicine · 2025Review
- Membranous nephropathy - an antigen-specific disease: a paradigm shift in the understanding of this disease.International journal of clinical and experimental pathology · 2025Article
- The Pathogenesis of Nephrotic Syndrome: A Perspective from B Cells.Kidney diseases (Basel, Switzerland) · 2024Review
- Analysis of the Sensitivity and Specificity of Histopathological Findings for Diagnosing Lupus Nephritis.Diagnostics (Basel, Switzerland) · 2024Article
- Technology Innovation for Discovering Renal Autoantibodies in Autoimmune Conditions.International journal of molecular sciences · 2024Review
- Association of Autoantibody Concentrations and Trajectories With Lupus Nephritis Histologic Features and Treatment Response.Arthritis & rheumatology (Hoboken, N.J.) · 2024Article
Corrections and comments
- Commented on by
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
Multiple autoantigens have been identified in membranous nephropathy (MN) by tissue-based proteomics. However, antigenic targets of disease are unknown for over 10% of patients with MN and over half of those with membranous lupus nephritis (MLN). Here, we identified multiple new targets in PLA2R-/THSD7A-/EXT-/NELL1-quadruple negative MN biopsies through mass spectrometry of immune complexes recovered from biopsy tissue of patients with MN. Patients with MN negative for these four antigens were identified from Arkana Laboratories case archives. Protein G immunoprecipitation recovered immune complexes from frozen biopsy tissue from 142 quadruple-negative cases and 278 cases of known antigen type, followed by interrogation by mass spectrometry. Potential putative antigens were confirmed through paraffin immunofluorescence and co-localization with IgG within immune deposits. Consecutive series of 165 cases of PLA2R-negative MN and 142 MLN biopsies were screened to determine the frequency for each potential antigen. Seven putative antigens were discovered within immune complexes from biopsies of patients with MN including FCN3, CD206, EEA1, SEZ6L2, NPR3, MST1, and VASN. Peptides from these proteins were not enriched in the 278 cases of known antigen type. Between three to 30 unique peptides were detected for each new target. Frequencies of each biomarker, determined by staining consecutive case series, ranged from under 1 to 4.9%. NPR3 and CD206 were only positive in index cases. All cases showed co-localization of IgG within the immune deposits. Thus, seven putative antigens were newly identified in MN and MLN. Due to the number of antigens identified, it is becoming impractical to type PLA2R-negative MN or MLN cases through immunostaining alone. A multiplex approach is needed for subtyping of these diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.